drugset / Trial / NCT04396574
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
RandomizedParallel-groupOpen-labelTreatment
Summary
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Timeline
- Start
- 2020-06-30
- Primary completion
- 2025-12-04
- Completion
- 2025-12-04
Outcome
Outcome not reported
Stopped (Business): “Study terminated due to strategic business decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lasmiditan | Small molecule | 50 mg | Oral |
| Subject | Lasmiditan | Small molecule | 100 mg | Oral |
| Subject | Lasmiditan | Small molecule | 200 mg | Oral |